Research
Hormonal
Combining basal insulin with a GLP-1 receptor agonist (GLP-1RA) significantly reduces HbA1c, body weight, and hypoglycemia risk compared to basal insulin alone or intensified insulin regimens.
If you are on basal insulin and your blood sugar is still high, ask your doctor about adding a GLP-1 receptor agonist (like liraglutide or dulaglutide). This combination lowers blood sugar more effectively than increasing insulin alone, helps you lose weight, and reduces the risk of low blood sugar episodes.
StrongSupportsHIGH confidence
A GLP-1RA plus basal insulin combination significantly reduced HbA1c compared to basal insulin alone while reducing body weight and the relative risk of hypoglycemia. Moreover, such a GLP-1RA plus basal insulin combination significantly reduced HbA1c compared to any other glucose-lowering therapy, almost doubling the likelihood of achieving the target HbA1c ≤ 7 %, with no increased risk of hypoglycemia and a significant weight reduction
Why this rating
Based on multiple meta-analyses of randomized controlled trials cited in the review.
Source
Pharmacotherapy of ‘treatment resistant’ type 2 diabetes
André Scheen · Expert Opinion on Pharmacotherapy · 2017
narrative_reviewCited 36×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →